1674 – Testing for mismatch repair deficiency (dMMR) in endometrial cancer to help determine eligibility for PBS-subsidised dostarlimab

Page last updated: 25 October 2021

Application Detail

Description of Medical Service

Immunohistochemistry (IHC) testing for identification of mismatch repair deficiency for eligibility to access dostarlimab on the PBS in patients with recurrent or advanced endometrial cancer.

Description of Medical Condition

Patients with recurrent or advanced endometrial cancer which are mismatch repair deficient, who have progressed following prior treatment.

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1360 KB)
Application Form (Word 298 KB)

Consultation Survey

Consultation Survey (PDF 584 KB)
Consultation Survey (Word 68 KB)

PASC Consultation
PASC consultation closed.

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC Email Bulletin to be notified when consultation opens for this application.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 1186 KB)
PICO Confirmation (Word 3820 KB)

Assessment Report


Public Summary Document


Meetings for this Application


12-13 August 2021